David Malcom Rodman Sells 2,171 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 2,171 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $29.71, for a total transaction of $64,500.41. Following the completion of the transaction, the insider directly owned 69,792 shares of the company’s stock, valued at approximately $2,073,520.32. The trade was a 3.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

• On Tuesday, May 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $29.36, for a total transaction of $186,377.28.
• On Wednesday, May 13th, David Malcom Rodman sold 14,056 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $28.58, for a total transaction of $401,720.48.
• On Friday, April 17th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $31.33, for a total transaction of $13,033.28.
• On Wednesday, April 15th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.66, for a total transaction of $175,585.68.
• On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.54, for a total transaction of $373,099.32.
• On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.38, for a total transaction of $59,414.60.
• On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.37, for a total transaction of $173,744.76.
• On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.26, for a total transaction of $369,163.08.
• On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.84, for a total transaction of $58,269.64.
• On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.59, for a total transaction of $11,505.03.

Mineralys Therapeutics Stock Up 1.5%

Shares of NASDAQ MLYS opened at $27.27 on Friday. Mineralys Therapeutics, Inc. has a twelve month low of $12.59 and a twelve month high of $47.65. The firm has a fifty day simple moving average of $27.09 and a 200 day simple moving average of $32.67. The company has a market capitalization of $2.25 billion, a PE ratio of -13.30 and a beta of 0.49.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.04. As a group, equities analysts expect that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on MLYS shares. HC Wainwright set a $56.00 price objective on shares of Mineralys Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 10th. Jefferies Financial Group reiterated a “hold” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a report on Friday, March 13th. Wall Street Zen cut shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. TD Cowen started coverage on shares of Mineralys Therapeutics in a report on Monday, April 27th. They set a “buy” rating for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Tuesday, April 21st. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $49.33.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC boosted its holdings in Mineralys Therapeutics by 2.7% during the first quarter. Affinity Asset Advisors LLC now owns 750,000 shares of the company’s stock worth $20,318,000 after purchasing an additional 20,000 shares during the last quarter. Renaissance Technologies LLC raised its position in Mineralys Therapeutics by 18.8% in the first quarter. Renaissance Technologies LLC now owns 382,800 shares of the company’s stock worth $10,370,000 after acquiring an additional 60,700 shares during the period. Pale Fire Capital SE raised its position in Mineralys Therapeutics by 3,431.3% in the first quarter. Pale Fire Capital SE now owns 365,626 shares of the company’s stock worth $9,905,000 after acquiring an additional 355,272 shares during the period. Sei Investments Co. boosted its stake in Mineralys Therapeutics by 33.2% in the first quarter. Sei Investments Co. now owns 11,692 shares of the company’s stock valued at $317,000 after acquiring an additional 2,912 shares during the last quarter. Finally, KBC Group NV purchased a new position in Mineralys Therapeutics in the first quarter valued at about $33,000. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.